Thus, both the NSABP B47 and the Treat CTC trial failed to confirm the hypothesis that women with early breast cancer showing low HER2 expression might benefit from treatment with trastuzumab following adjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.